Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Summary

Immune checkpoint inhibitors, such as programmed death 1 (PD-1) and programmed cell death-Ligand 1 (PD-L1), offer new approaches for systemic treatment of tumors, but clinical efficacy remains limited. Previous studies by our team have found that methotrexate can activate anti-tumor immunity. The discovery of a new effect of this drug will improve tumor response to immunotherapy and prognosis of patients.

Timeline

Start

2021-11-15

Primary completion

2023-12-31

Completion

2026-12-31

Drugs

Indications